In their assessment of long-term outcomes in 57 intracranial HB treated with SRS, Hanakita and colleagues reported 5- and 10-year tumor control rates of 67 and 44%, respectively, for sporadic HB compared to 97 and 83% , respectively, for VHL-related HB (67). The gene discussed is VHL; the disease is neoplasm.